Pyxis Oncology, Inc. PYXS 深 滬
等待開盤 12-23 09:30:00 美东时间
1.19
-0.085
-6.67%
華盛通- 最 高1.39
- 今 開1.31
- 成交量 315.30万股
- 最 低 1.16
- 昨 收 1.275
- 總市值 7409.44万
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 5.06%
- 52周最低 0.8332
- 委 比 -24.02%
- 總股本 6226.42万
- 歷史最高 19.00
- 量 比 0.88
- 振 幅 18.04%
- 歷史最低 0.8332
- 每 手 1
- 風險率 1.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
12-22 15:05
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
12-19 22:07
Pyxis Oncology shares are trading lower. The company announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin.
Pyxis Oncology shares are trading lower. The company announced preliminary data...
12-18 22:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
12-18 20:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8
Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and raises the price target from $5 to $8.
11-24 22:04
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7
Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $5 to $7.
11-04 23:37
Pyxis Oncology shares are trading higher. The company reported Q3 financial results.
Pyxis Oncology shares are trading higher. The company reported Q3 financial res...
11-04 00:50
Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.04 percent. This is unchanged from the same period last year.
11-03 20:09
